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ABSTRACT 
The incidence of diabetes is predicted to in- 
crease to 21% by 2050. Currently, one third of US 
adults are obese and over 11% of these indi- 
viduals have diabetes. Due to the growing need 
for therapeutic intervention to control and/or 
stabilize this increase in the incidence of diabe- 
tes in Western communities, gaining a compre- 
hensive understanding of the association be- 
tween obesity and Type 2 diabetes has become 
increasingly important to diabetes research. The 
increased cell senescence associated with dia- 
betes has been associated with the limited abil- 
ity of cells to divide, with indication of telomere 
shortening and genomic instability of the cells. 
Obese individuals have shorter telomeres sug- 
gesting an inverse relationship between adipos- 
ity and telomere length. The implication that 
Type 2 diabetes has on biological aging is of 
particular interest since telomere shortening in 
obesity and diabetes has been associated with 
an early risk for dementia and even progression 
to Alzheimer’s disease (AD). Lifestyle, nutrition 
and longevity are closely related and cellular 
senescence has been associated with telomere 
shortening and connected to longevity. Diet, 
cholesterol lowering drugs and exercise that 
control food intake and glucose tolerance in 
aging and diabetic individuals, via connections 
between liver circadian clocks and the su- 
prachiasmatic nucleus in the brain, also have 
been shown to alter telomere lengths. Lifestyle 
interventions, such as diets low in fat and exer- 
cise, target the rise in obesity and associated 
telomere shortening by delaying or preventing 
the onset of Type 2 diabetes. The implementa- 
tion of these anti-aging therapies early in life 
may prevent calorie overload and activation of 
calorie sensitive genes such as Sirtuin 1 (Sirt1). 
This may maintain telomere length and the con- 
trol of obesity, which is linked to cardiovascular 
disease, diabetes and accelerates aging and AD. 
 
Keywords: Telomere; Sirtuin 1; Lifestyle; Nutrition; 
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1. BACKGROUND 
Age-related diseases are becoming a major concern as 
the world’s population grows older due to advances in 
medical technology, health and nutrition. Dementia ac- 
counts for a large proportion of age-related diseases and 
is characterised clinically by deterioration in cognitive 
processing, including memory. Alzheimer’s disease (AD) 
is the most common form of age-related dementia. The 
insulin-resistance syndrome has in many studies been 
associated with diabetes and AD. The social and eco- 
nomic consequences of this disease present a significant 
challenge to society, and it is imperative that strategies to 
prevent or delay the onset of diabetes are developed to 
prevent the proportion of the age related group with car- 
diovascular dysfunction progressing towards AD. AD is 
a neurodegenerative disease which presents clinically 
with key clinical symptoms including progressive de- 
cline in memory. Risk factors for AD include old age, 
family history of dementia, APOE 4 genotype, Down’s 
syndrome, obesity and type 2 diabetes.  
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Epidemiological studies clearly suggest that human 
obesity is associated with the increased risk for athero- 
sclerosis, contributing to the early onset of coronary ar- 
tery disease and diabetes. The susceptibility of humans to 
obesity is far higher compared with other species [1]. 
Amongst mammals, humans have been reported to have 
the highest level of fat than any other species as genes 
and environmental factors predispose humans to obesity 
[2]. In an editorial by Testa and Ceriello published in 
2007, the increased cell senescence associated with 
diabetes was associated with the limited ability of cells to 
divide with indication of cellular alteration in genes and 
genomic instability of the cells [3]. Human obesity may 
complete the pathogenetic loop between cell senescence 
and diabetes through teleomere shortening and an asso- 
ciation with an increased risk for atherosclerosis. This in 
turn contributes to the early onset of coronary artery dis- 
ease and diabetes.  
Visceral obesity in particular increases the risk of 
atherosclerosis owing to both insulin resistance and 
dyslipoproteinemia and this global rise in obesity is pos- 
sibly linked to telomere disease. Obesity has been closely 
linked to diabetes [4,5] and the association of obesity and 
telomere shortening has now been reported [6]. In par- 
ticular, telomere length, high density lipoprotein (HDL) 
cholesterol [7] and other risk factors for atherosclerosis 
that could be exacerbated by obesity-associated telomere 
dysfunction include hypertension and hyperlipidemia 
(particularly hypertriglyceridemia). These are also risk 
factors for AD. Circadian desynchrony and hyperphagia 
are also related to obesity and anti-aging, circadian 
proteins, such as sirtuins are known to regulate several 
cell functions by deacetylating both histone and non- 
hisotone targets. Sirtuins are NAD(+)dependent class III 
histone deacetylase (HDAC) proteins that target tran- 
scription factors to adapt gene expression to metabolic 
activity. Sirtuin 1 (Sirt1) is linked to life span, obesity 
and cardiovascular disease with effects on liver steatosis, 
inflammation, food intake, energy metabolism, cognition, 
mitochondrial biogenesis, neurogenesis, glucose/chole- 
sterol metabolism and amyloidosis [8-22]. Regulation of 
Sirt1 by calorie restriction in extending life span has 
been recognized. Novel dietary acitvators of Sirt1 are 
required and designing compounds that have therapeutic 
potential for the control of telomere shortening, clock 
circuitry and generation of Aβ for the treatment of AD is 
the focus of several research groups [23-26].  
Obesity in humans is seen to be associated with de- 
creased life span in man and is an excellent model for the 
assessment of cell senescence, inflammation, diabetes 
and AD [27-31]. The understanding of alterations in 
genes/genomic stability and the environment in the aging 
brain has been the subject of various anti-aging programs 
as well as the mechanisms involved in anti-aging strate- 
gies related to low fat diets and reversing brain aging. 
The association between diabetes and neurodegenerative 
diseases (AD and Parkinson’s disease) have related the 
majority of the genes to cholesterol metabolism, cyto- 
kines and inflammation. Environmental factors such as 
diet and circadian desynchrony have become important 
in Western countries since interests in the global increase 
in obesity is possbily linked to diabetes, timing of food 
consumption, metabolic activity and alterations in adi- 
pose tissue leading to a release of adipokines (leptin and 
adiponectin). These adipokines increase with age and are 
associated with age related pathological alterations in 
cytokines associated with neuroinflammation [32,33]. 
2. CONVERGENCE OF MECHANISMS 
LINKING OBESITY TO DIABETES AND 
ACCELERATION OF AGING AND 
ALZHEIMER’S DISEASE 
The mechanism linking obesity with diabetes is un-
clear but the global epidemic indicates that most patients 
with type 2 diabetes are obese; over a third (34%) of US 
adults are obese and about 11% of these individuals have 
diabetes [4]. The incidence of diabetes is predicated to 
increase to 21% by 2050 [5]. The understanding of 
mechanisms which connects these two diseases has be- 
come important to diabetes research since therapeutics to 
control and stabilize the increase in the incidence of dia- 
betes in Western communities is required. As lipids and 
proteins accumulate in cells, the cells become impaired 
and can no longer divide, decreasing the lifespan of the 
cell resulting in cell telomeres that have eroded or short- 
ened with cell senescence. The telomere is a repeating 
sequence of DNA at the end of a chromosome  
(TTAGGG)n [34,35]. Aging results in a progressive loss 
of telomere repeats and with telomere shortening the cell 
ceases to replicate with alterations in lipid and protein 
metabolism with eventual cell death [34,35]. Obese indi- 
viduals have shorter telomeres and an inverse relation- 
ship has been found with adiposity and telomere length 
[6,36,37]. The pathogenetic loop between obesity and 
diabetes has recently been related to Sirt1 which is in- 
volved in cellular senescence. The genomic instability 
and telomere dysfunction observed in obesity is now 
closely associated with the pathogenesis of diabetes, 
dyslipidemia and cardiovascular disease. Diabetes, ge- 
netic and environmental factors have been reported to 
stress telomeres [38] through telomere shortening (Fig- 
ure 1).  
Sirt1 and cell senescence has been closely linked to 
telomere biology and global DNA repair which provides 
mechanistic explanations for SIRT1 functions, in protec- 
tion from DNA damage, and thus genomic stability 
[39,40]. Sirt1 has been closely linked to telomerase 
which is a ribonucleoprotein (RNP) complex responsible  
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Figure 1. Nutrition, lifestyle and aging determine telomere-
length and genomic stability. 
 
for the elongation of telomeres to maintain genomic in- 
tegrity. Telomerase is composed of the telomerase re- 
verse transcriptase (TERT) and telomerase RNA compo- 
nents (TERC). These factors regulate the catalytic activ- 
ity of telomerase [41]. Telomerase protects cells from 
apoptosis via the maintenance of genomic integrity by 
stabilizing telomeres and adding DNA, in mediating cell 
survival and anti-apoptotic functions against various cy- 
totoxic stresses [42,43]. Telomerase is closely connected 
to telomere length maintenance and control of genes in- 
volved in growth and cell proliferation [44]. 
Anti-aging strategies that target telomere shortening in 
diabetes is of particular interest to biological aging since 
telomere shortening has been associated as an early risk 
for dementia [45,46]. Age-related changes in AD lead to 
neuronal apoptosis and therapy to delay the onset and 
even progression of Alzheimer’s disease are urgently 
required. Nutrition related to low fat diets and drugs that 
reduce intestinal absorption of fat with modulation of 
adipose tissue Sirt1 activity may improve the adipocyte 
brain crosstalk that may be assessed as a possible treat- 
ment of neuronal diseases that afflict diabetic and AD 
individuals. Sirt1 is essential for neurogenesis and calo- 
rie restriction activates Sirt1 with effects on longevity by 
modulation of phosphoinositide 3 kinase pathway that 
determines life span [47-49]. The role of Sirt1 in brain 
metabolic regulation and synaptic plasticity has been 
shown and maintenance of Sirt1 expression by calorie 
restriction regulates lipid metabolism and energy expen- 
diture [19]. Age associated cardiovascular changes have 
been strongly associated with alterations in Sirt1 [8-11] 
and genetic as well as experimental evidence of its con- 
trol of lifespan is of interest to the areas of diabetes, 
neurodegeneration and AD. Telomere and telomerase 
activity has now taken an important place in AD thera- 
peutics, using telomere length and telomerase activity in 
the determination of neuronal populations in these indi- 
viduals [50,51]. Sirt1 and its role in AD is of interest 
with reviews that indicate that Sirt1 is closely connected 
to Abeta production, telomere maintenance and stem cell 
aging [39,40,52,53]. Interests in Sirt1 control of telom- 
erase is of interest to diabetes and AD with recent public- 
cations suggesting telomerase inhibition is involved with 
abeta cell apoptosis. In AD, transgenic mice telomere 
length has also shown to be associated with amyloid pa- 
thology with indications that Sirt1 expression and activ- 
ity is essential to neuronal population maintenance and 
prevention of AD. 
3. LIFESTYLE, DIET AND DRUG  
CONNECTIONS TO DIABETES AND 
ALZHEIMER’S DISEASE 
The estimate in global deaths due to diabetes was es- 
timated to be 5.2% of all deaths in 2009 [54]. In poorer 
countries, mortality related to diabetes was 2% - 3%, in 
countries such as the USA, Canada and the middle east 
the mortality was approx. 8% and for individuals be- 
tween 35 - 64 years between 6% - 27% of the deaths 
were attributable to diabetes [55]. In 2011, the largest 
number of people with diabetes were in India, China, 
United States of America and the Russian Federation and 
mortality in 2011 reached 8.2% of the global population 
[55] Nutrition and longevity are closely related and cel- 
lular senescence has been associated with telomere 
shortening as well as the life span of the organism 
[34,35]. Apart from nutrition, minor alcohol consumption 
has been shown in midlife to shorten telomeres and ac- 
celerate aging in older individuals [56,57]. Diet, choles- 
terol lowering drugs and exercise may improve telomere 
lengths. This may provide the classical evolutionary 
conserved environment to suit anti-inflammatory proc- 
esses which control of food intake and circadian rhythm 
and promote normal liver and brain, lipid and protein 
homeostasis, ultimately preventing glucose intolerance 
and diabetes.  
Sirt1 (nutrient sensitive gene) is closely linked to food 
intake and the prevention of diabetes, which is linked to 
amyloidosis and may offer a potential therapy for AD 
treatment (Figure 2, [58,59]). Interests in high fat intake 
and the consumption of fat at specific times of the day 
requires further investigation as a mechanism for diabe- 
tes and AD induction. Drugs that reduce intestinal ab- 
sorption of fat will modulate the tissue anti-aging protein 
Sirt1, improving the adipocyte brain crosstalk that should 
be assessed as a possible treatment of neuronal diseases 
such as AD.  
In recent years, the world diabetes epidemic now in- 
cludes younger individuals and has become of concern 
because of the risk for telomere shortening and non-al- 
coholic liver disease (NAFLD) [60]. In Western coun- 
tries, accelerated aging is associated with NAFLD and 
has reached epidemic levels, with 40 % of the commu-
nity with the disease and up to 20% of these individuals 
developing hepatic fibrosis and cirrhosis [61,62]. In-  
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Figure 2. High fat and high cholesterol diets affect Sirt1 con-
trol of circadian rhythms with liver steatosis and effects on 
peripheral and brain amyloid beta metabolism. 
 
dividuals with longer lifespan have been shown to be 
diabetes free and increased mortality was attributed to 
increases in obesity [61]. Age related pathologies, such 
as NAFLD, that have been linked to Type 2 diabetes and 
AD, indicate association between insulin resistance, oxi- 
dative stress and telomere shortening [63]. Hepatocyte 
senescence, telomere shortening, nuclear size altera- 
tions and telomere foci have been closely associated to 
NAFLD and indicate mitochondrial dysfunction and lack 
of cell cycle progression beyond the cell cycle G1/S 
phase [64-68]. Interests in telomere shortening and insu- 
lin resistance indicate that the suprachiasmatic nucleus 
(SCN), which closely regu- lates peripheral clocks such 
as the liver (NAFLD) and adipose tissue (increased adi- 
posity), is abnormal with relevance to the pathophysiol- 
ogy of disease [62] progression in obese, diabetic and 
AD individuals [69-72]. 
Drug therapies that target the brain have not been 
successful in preventing amyloid deposition but drugs 
that target the periphery may be promising by length- 
ening peripheral cell telomeres, lowering plasma fat and 
cholesterol and activating adipose tissue, liver and brain 
metabolic activity. Interest in Sirt1 modulation of various 
proteins that regulate cellular inflammation, glucose and 
cholesterol homeostasis are relevant to diabetes and 
neurodegeneration. Regulation of this calorie-restricted 
gene, Sirt1, as an important control that targets obesity, 
diabetes and brain aging by suppression of inflammation 
as well as maintenance of neuroprotective mechanisms 
that facilitate normal food intake and vitamin E transport 
to the central nervous system essential for growth of 
neurons has been the interest of anti-aging research stud- 
ies. Designing compounds for the regulation of Sirt1 to 
extend life span has been recognized and activators of 
Sirt1 in order for telomere maintenance have been re- 
ported. The use of melatonin, which is involved in 
telomere maintenace and circadian clock control [40], is 
relevant for the treatment of diabetes and AD as compared 
with other circadian rhythm drugs such as the ben- 
zodiazepines or non-benzodiazepines.  
The relationship between telomere erosion and apoE4 
is closely associated [23] with the role of apolipoprotein 
E and its connections with inflammation/cytokines [73, 
74] as an important control of telomere attrition in the 
periphery and the brain. The connections between dys- 
lipidemia and inflammation have been reported in diabe- 
tes, where inflammation in the blood plasma and altered 
cytokines have been associated with changes in lipid 
metabolism (increased triglyceride and low HDL) and in 
the brain, alterations in the light/dark cycle [75]. Drugs 
involved with telomere lengthening are possibly in- 
volved in the adaptation of the organism to the environ- 
ment and require regulation of liver glucose and choles-
terol and are controlled by dietary fat and cholesterol 
intake (Figure 2, [76-78]). The mechanism by which the 
4 allele promotes AD risk could be associated with dia-
betes and telomere shortening as well as with abnormal 
regulation of food intake, explaining the hyperphagia 
associated changes in diabetes and AD [79-81]. 
4. NUTRITIONAL SCIENCE AND DRUGS 
DELAY OBESITY AND SEVERITY OF 
DIABETES LINKED TO AGING AND 
ALZHEIMER’S DISEASE 
Biological aging is closely connected to telomere 
length and control of cellular senescence. Each time a 
cell replicates and divides the telomere loses some of its 
length. Eventually the telomere runs out and the cell can 
no longer divide and rejuvenate, triggering a poor state 
of cell health that contributes to disease risk and eventual 
cell death. Telomere length is epigenetically regulated 
and affected by nutrients, alcohol, drugs, genetics and the 
environment (Figure 3). It is interesting to note that te- 
lomere shortening would be accelerated by synergistic 
effects of mixing alcohol and fats such as palmitic acid 
with increased genomic instability and DNA breakdown. 
The effective function of telomeres require methylation, 
which uses nutrients like methionine, an essential amino 
acid that serves as a methyl donor and is involved with 
the biosynthesis of other nutrients. Improper conversion 
is associated with production of homocysteine and 
atherosclerosis, methylsulfonylmethane, sulphur, choline, 
and trimethylglycine, as building blocks and allow regu-
lation of genes by appropriate telomeres. Vitamins such 
as vitamin B12, folic acid, and vitamin B6 play multiple 
roles in genomic stability as well. Foods that are impor-
tant include protein, eggs, cottage cheese, dairy, red meat, 
chicken, legumes, duck, nuts, and seeds. Antioxidants 
and vitamins C, D and E are essential and maintain ge-
nomic stability as well as telomeres. A lack of antioxi-
dants leads to increased free radical damage and more 
risk for damage to telomeres. Minerals, such as mag-  
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Figure 3. Potential anti-aging therapies (left) delay the aging 
process by telomere maintenance and control of DNA damage. 
 
nesium, are needed by many enzymes involved with 
DNA replication and repair and total magnesium intake 
should be between 400 mg - 800 mg per day. Zinc is in- 
timately involved with DNA as well as DNA repair. The 
lack of zinc causes an excessive amount of DNA strand 
breakage and telomere depletion. Inflammation and stress 
shorten telomeres and omega 3 fatty acids (eicosapen- 
taenoic acid/docosahexaenoic acid) are important as ba- 
sic nutrients to preserve telomeres. Nutrients such as 
quercetin, green tea catechins, grape seed extract, curcu- 
min, and resveratrol also help maintain telomeres, with 
both grape seed extract and curcumin showing the ability 
to generate longer telomeres. In addition, resveratrol and 
calorie restriction activate Sirt1 with prevention of te-
lomere attrition. 
Drug evaluation and differences in therapeutic effects 
of various drugs may indicate that the telomere length of 
tested rodents or diseased individuals may be related to 
genetic, diet and environmental conditions. Drugs such 
as statins have been shown to control telomere/telom- 
erase in peripheral leukocytes from individuals with car-
diovascular disease [82,83] and have provided potential 
anti-aging therapy for diabetes and AD. Statins, however, 
are not Sirt1 activators and Sirt1 activators are primarily 
in control of telomere length and attrition. The close as-
sociation of hyperphagia with diabetes and AD indicate 
that fat consumption (calorie excess) may have marked 
effects on telomeres/telomerase activation [42,43]. Ex-
perimental drugs in mice, such as an acyl coA cholesterol 
acyltransferase (ACAT) inhibitor Avasimibe, that pre-
vents fat absorption (calorie excess) have shown clear 
effects on body weight, liver and brain growth in mice 
consuming high fat diets (Abstract AD/PD Italy, 2013) 
possibly as a Sirt1/telomerase activator. Interests in te-
lomerase activation have increased with the recent find-
ings of TA-65 (purified from the root of Astragalus 
membranaceus/legume), a small molecule activator of 
telomerase involved in glucose regulation [84]. In con-
trast, various drugs that are Sirt1 inhibitors should be 
assessed with various diets since telomere shortening and 
attrition by Sirt1 inhibitors will lead to degenerative dis-
eases such as obesity, diabetes, cardiovascular disease 
and AD. Lifestyles changes such as diet and exercise 
early in the life of obese or diabetic individuals may 
prevent circadian alterations and calorie overload. Con-
tinued Sirt1 activation and the maintenance of peripheral 
(liver) and CNS (brain) cell telomeres with prevention of 
obesity linked to diabetes may decrease accelerated ag-
ing and the risk of AD. 
5. CONCLUSION 
The biological mechanism behind the global epidemic 
of obesity and Type 2 diabetes has become important to 
Alzheimer’s research since therapeutic interventions with 
the potential to control and stabilize their increased inci-
dence in Western society may also have the potential to 
delay the acceleration in aging and AD. The increased 
cell senescence associated with obesity and diabetes has 
indicated an increase in telomere shortening and genomic 
instability of the cells from these individuals. Stabiliza-
tion of biological aging is of particular interest in obesity 
and diabetes and the delay of telomere shortening in 
these individuals may result in a decrease in dementia 
and even a delay in the progression to (AD). Lifestyle, 
nutrition and longevity are closely connected to life span 
of obese and Type 2 diabetic individuals and therapeutics 
such as cholesterol lowering drugs, exercise and diets 
low in fat, target the rise in obesity and associated te-
lomere shortening by delaying or preventing the onset of 
Type 2 diabetes. Implementing these anti-aging therapies 
early in life may prevent calorie overload and activation 
of calorie sensitive genes, such as (Sirt1), that may main- 
tain telomere length and the control of obesity, which is 
linked to cardiovascular disease, diabetes and accelerates 
aging and AD. 
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